Full-Time

Associate Field Service Engineer

Electrophysiology

Updated on 8/3/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

CA$56k - CA$89.7k/yr

Montreal, QC, Canada

In Person

Must be based in the Montreal area and travel extensively throughout Eastern Canada and elsewhere as needed.

Associate's

Category
Electrical Engineering (1)
Required Skills
Microsoft Office
Inventory Management
CRM

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A two- or three-year college diploma or Quebec Technical DEC in Biomedical Engineering Technology, Electronics Engineering Technology, Engineering Technology, or a related technical field.
  • A comparable combination of technical education, field service experience, biomedical equipment support, electronics troubleshooting, or other relevant hands-on technical experience may be considered.
  • Bilingual proficiency in French and English, written and spoken, is required.
  • Ability to work in a field-based role, with approximately 80% field time and 20% office or remote administrative work.
  • Ability to travel on short notice to support customer and business needs.
  • Ability to work weekends, evenings, and off-hours as required.
  • Strong organizational skills and the ability to manage multiple priorities.
  • Working knowledge of Microsoft Office applications.
  • Strong troubleshooting and problem-solving skills.
  • Demonstrated commitment to customer satisfaction and continuous improvement.
  • Willingness and ability to travel extensively, including frequent air travel.
  • Ability to operate a company vehicle and maintain an appropriate valid driver's license.
  • Ability to meet the physical requirements of the role, including heavy lifting, prolonged standing, bending, and handling equipment.
  • Respect and consistently follow safety rules and procedures.
  • Use required personal protective equipment and safety devices.
  • Participate in incident investigations as required.
Responsibilities
  • Provide on-site and remote technical support to internal and external customers.
  • Schedule and perform equipment installation, operation checks, repairs, upgrades, and service activities within the assigned territory.
  • Shadow and support experienced Field Service Engineers during installations, maintenance activities, troubleshooting, and repairs.
  • Support preventive maintenance programs and maintain accurate service and performance records for supported equipment.
  • Evaluate, diagnose, and repair malfunctioning equipment in response to assigned service work orders.
  • Respond to urgent customer service requests, identify root causes, and implement appropriate corrective and preventive actions.
  • Provide technology support to customers and internal stakeholders when escalation or additional technical guidance is required.
  • Support customer expectations before, during, and after service interactions to help ensure product performance and customer satisfaction.
  • Review complaints, parts usage, and system performance data to identify trends, recommend improvements, and support corrective and preventive action plans.
  • Complete service documentation, administrative tasks, and required paperwork in accordance with applicable policies and procedures.
  • Create, update, and close work orders in the customer relationship management system accurately and in a timely manner.
  • Coordinate parts returns and maintain accurate tracking of parts and equipment usage.
  • Manage assigned inventory and complete required inventory audits.
  • Complete required training for supported products, systems, processes, and compliance requirements.
  • Participate in complaint review, investigation, and related follow-up activities.
  • Communicate business-related issues, risks, or opportunities to the next management level as appropriate.
  • Follow all company guidelines related to health, safety, and environmental practices.
  • Ensure personal and company compliance with all applicable federal, provincial, local, and company regulations, policies, and procedures.
  • Perform additional Field Service Engineer duties as required to support business and customer needs.
Desired Qualifications
  • Education or training that supports medical device service, electromechanical systems, clinical technology, customer-facing technical support, or regulated service environments.
  • Knowledge of troubleshooting principles, service practices, and field support processes.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • TREMFYA, INLEXZO, and ICOTYDE are accelerating, offsetting STELARA's 55% quarterly collapse.
  • FDA-cleared OTTAVA begins US commercialization, expanding J&J's robotic surgery platform this year.

What critics are saying

  • The July 2026 talc settlement leaves future claims unresolved and UK litigation active.
  • STELARA biosimilars and Imbruvica competition keep eroding legacy pharma cash flows in 2026.
  • Abiomed weakened after the UK Impella study, and PROTECT IV data arrives in 2027.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and consumer brands across entrenched hospital workflows.
  • Its scale funds constant launches, from TREMFYA to OTTAVA, across multiple therapies.
  • Deep surgeon and hospital switching costs protect MedTech franchises like da Vinci-adjacent competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 4th, 2026
JNJ returns $85B to shareholders but stock still lags S&P 500 by 13%

Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.

Yahoo Finance
Jul 31st, 2026
J&J beats estimates with $25.3B revenue, raises guidance to $101.1B for the year

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.

Yahoo Finance
Jul 28th, 2026
J&J to pay $5.5B to settle 76,000 talc baby powder cancer lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.

Yahoo Finance
Jul 27th, 2026
J&J's MedTech sales rise 4.5% to $8.93B in Q2 amid Abiomed weakness and electrophysiology pressure

Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.

Yahoo Finance
Jul 27th, 2026
J&J exec sells $5.8M in shares as stock climbs 27% despite biosimilar and competition headwinds

Johnson & Johnson executive Vanessa Broadhurst sold 23,054 shares worth approximately $5.8 million on 20 July, representing about half her stake. The stock has risen 27% this year. J&J has restructured through recent spin-offs of its consumer health and orthopaedics units to focus on higher-growth areas. Management targets 6% operational sales growth for 2026, aiming for double-digit growth by decade's end. Recent quarterly revenue increased 6.6% year-over-year, with oncology up 17.3%. Darzalex grew nearly 18%, whilst Tremfya surged 72.5%. Management raised full-year earnings guidance. However, older blockbuster Stelara declined due to biosimilar competition, and Imbruvica dropped 18.5% on competitive pressure. The stock trades at roughly 21-22 times forward earnings, about 10% above sector median, with a 2.2% dividend yield.